Processa Pharmaceuticals, Inc. Quarterly report [Sections 13 or 15(d)]

Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details) (Parenthetical) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Interim Period, Costs Not Allocable [Line Items]
Personnel costs include employee stock-based compensation expense	$ 92,105	$ 203,251	$ 188,068	$ 430,962
Research and Development Personnel Costs [Member]
Interim Period, Costs Not Allocable [Line Items]
Personnel costs include employee stock-based compensation expense	17,145	8,613	34,289	55,333
General and Administrative Personnel Costs [Member]
Interim Period, Costs Not Allocable [Line Items]
Personnel costs include employee stock-based compensation expense	$ 48,528	$ 122,655	$ 100,915	$ 245,310